Pharmaceutical firm Cadila Healthcare today announced that it has received USFDA approval to conduct clinical trials for ZYGK1, a new molecular entity (NME), for treating diabetes. Cadila Healthcare said the new molecular entity (NME) being designed and developed at the company’s research centre, is a potent and orally administered small molecule glucokinase activator. The...